U.S. stocks recoiled Tuesday, the day after the NASDAQ Composite climbed above 5000 for the first time in nearly 15 years.
Traders said Tuesday’s decline in equities is to be predictable, as it comes a day after the Dow industrials and the S&P 500 index closed at all-time highs and the NASDAQ Composite returned to above the 5000 level for the first time since March 2000.
Insights about those U.S. Stocks that are active during the recent trade, are depicted underneath:
Sirius XM Holdings Inc. (NASDAQ:SIRI)’s shares picked up 0.88%, and is now trading at $4.00, soon after the news release that Sirius XM Holdings Inc., declared that its partner, Sirius XM Radio Inc., intends to offer $750 million of Senior Notes due 2025 to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended, and outside the United States in compliance with Regulation S of the Securities Act.
The company intends to use the net proceeds from the offering for general corporate purposes, which may comprise, from time to time and as market conditions warrant, the repayment, repurchase, redemption, defeasance or tender of its outstanding indebtedness, counting any borrowings outstanding under its revolving credit facility, and dividends or loans to SiriusXM, its parent corporation, to fund share repurchases of SiriusXM ordinary stock. Pending application of these amounts, the company presently anticipates to maintain any excess amount as cash on hand.
The securities have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration, except following an exemption from the registration requirements of the Securities Act and applicable state securities laws.
This declaration is neither an offer to sell nor a solicitation to buy any of these securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
Sirius XM Holdings Inc. (SIRI) through its subsidiaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.
Micron Technology, Inc. (NASDAQ:MU) declined -3.55%, and is now trading at $30.13. The stock has the beta value of 1.58, and its volatility for the week is 2.99%, while for the month it is 2.88%. The company has the market capitalization of $33.23B. The mean recommendation of analysts for this stock is 1.90.(where 1=Buy, 5=Sale).
Micron Technology, Inc. (NASDAQ:MU) together with its subsidiaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Alliance Bancorp Inc of Pennsylvania (NASDAQ:ALLB), enhanced 21.47%, and is now trading at $21.27, soon after the news release that WSFS Financial Corporation (WSFS) and Alliance Bancorp Inc of Pennsylvania, jointly declared the signing of a definitive contract and plan of merger whereby WSFS Financial Corporation will attain Alliance Bancorp, Inc. of Pennsylvania. Upon the closing of the transaction, Alliance Bank, the wholly owned bank partner of Alliance Bancorp, Inc. of Pennsylvania will merge into WSFS Financial Corporation’s wholly owned bank partner, WSFS Bank. Headquartered in Broomall, Pennsylvania, Alliance Bank opened in 1938 as an independent, locally-managed institution dedicated to providing the highest quality community banking services predominantly to Delaware County and neighboring Chester County residents. Alliance Bank stated about $421 million in assets, $310 million in loans and $345 million in deposits as of December 31, 2014 and serves its customers from eight branch locations. Following the merger, WSFS will have 17 locations in southeastern Pennsylvania, counting 11 in Delaware County.
WSFS President and Chief Executive Officer, Mark A. Turner said, “We are happy to declare our partnership with Alliance Bank, our fourth attainment in recent years and our largest to date. Alliance’s eight locations and over three-quarters of a century heritage in southeastern Pennsylvania are a great complement to our branch network and add important relationships to our banking franchise. We believe we have aligned ourselves with a terrific partner in Alliance Bank, as they also share an extraordinary commitment to Customers, Communities and Associates. Southeastern Pennsylvania is a highly desirable and complementary market expansion opportunity for our franchise and we look forward to further expanding our presence in the market.”
The transaction is valued at about $92.0 million. Under the terms of the contract, which has been approved by the boards of directors of both companies, shareholders of Alliance Bancorp, Inc. of Pennsylvania will be entitled to elect to receive either 0.28955 shares of WSFS ordinary stock or $22.00 in cash for each ordinary share of Alliance Bancorp, Inc. of Pennsylvania, subject to an overall allocation of exchanged shares into 70% ordinary stock and 30% cash. The closing is anticipated to occur during the fourth quarter of 2015, subject to approval by Alliance Bancorp, Inc. of Pennsylvania shareholders, regulatory approvals and other customary closing conditions.
Alliance Bancorp Inc of Pennsylvania (NASDAQ:ALLB) operates as the bank holding company for Alliance Bank that provides community banking services in Pennsylvania. Its deposit instruments comprise NOW accounts, money market accounts, savings accounts, and term certificate accounts, in addition to passbook and statement savings accounts, non-interest bearing accounts, and certificates of deposit.
MannKind Corp. (NASDAQ:MNKD), dropped -9.64%, and is now trading at $6.00, soon after the news release that MannKind Corp., stated financial results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter, the company’s operating expenses declined 35% contrast to the similar quarter in 2013. Research and development costs were significantly lower, mainly due to a reduction in non-cash compensation expenses and much lower clinical trial expenses following the completion of the Affinity studies in 2013. General and administrative costs declined 29%, mainly reflecting lower non-cash compensation expenses.
For the full year 2014, the company’s total operating expenses raised modestly, with a decrease in research and development costs offset by an raise in general and administrative costs. Research and development costs reduced due to the completion of our Affinity trials, the pivotal clinical trials regarding the efficacy and safety of our novel inhaled insulin, Afrezza. Higher general and administrative costs resulted primarily from raised professional fees, principally related to the negotiation and completion of a partnership contract with Sanofi. In addition, professional fees reflected a noteworthy expansion in our program to identify, screen and fully evaluate new product opportunities that will best take advantage of the unique advantages of our Technosphere(R) drug delivery technology.
“After achieving a number of noteworthy milestones during 2014, we began the commercial production of Afrezza during the fourth quarter of the year,” said Hakan Edstrom, MannKind’s President and Chief Executive Officer. “With our flagship product, Afrezza(C), in the early stages of its commercial launch in the United States, we now enter a very exciting new phase for MannKind.”
MannKind Corp. (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
